<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">55852</article-id><article-id pub-id-type="doi">10.7554/eLife.55852</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-109920"><name><surname>Athukoralage</surname><given-names>Januka S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1666-0180</contrib-id><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-109921"><name><surname>Graham</surname><given-names>Shirley</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2608-3815</contrib-id><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174792"><name><surname>Rouillon</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref></contrib><contrib contrib-type="author" id="author-109922"><name><surname>Grüschow</surname><given-names>Sabine</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174791"><name><surname>Czekster</surname><given-names>Clarissa M</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-33503"><name><surname>White</surname><given-names>Malcolm F</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1543-9342</contrib-id><email>mfw2@st-and.ac.uk</email><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution>Biomedical Sciences Research Complex, School of Biology, University of St Andrews</institution><addr-line><named-content content-type="city">St Andrews</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Wiedenheft</surname><given-names>Blake</given-names></name><role>Reviewing Editor</role><aff><institution>Montana State University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Storz</surname><given-names>Gisela</given-names></name><role>Senior Editor</role><aff><institution>National Institute of Child Health and Human Development</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Department of Molecular Sensory Systems, Center of Advanced European Studies and Research (Stiftung Caesar), Bonn, Germany</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>27</day><month>04</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e55852</elocation-id><history><date date-type="received" iso-8601-date="2020-02-12"><day>12</day><month>02</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-04-26"><day>26</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Athukoralage et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Athukoralage et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-55852-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="article-reference" xlink:href="10.7554/eLife.36734"/><abstract><p>Cyclic nucleotide second messengers are increasingly implicated in prokaryotic anti-viral defence systems. Type III CRISPR systems synthesise cyclic oligoadenylate (cOA) upon detecting foreign RNA, activating ancillary nucleases that can be toxic to cells, necessitating mechanisms to remove cOA in systems that operate via immunity rather than abortive infection. Previously, we demonstrated that the <italic>Sulfolobus solfataricus</italic> type III-D CRISPR complex generates cyclic tetra-adenylate (cA<sub>4</sub>), activating the ribonuclease Csx1, and showed that subsequent RNA cleavage and dissociation acts as an ‘off-switch’ for the cyclase activity. Subsequently, we identified the cellular ring nuclease Crn1, which slowly degrades cA<sub>4</sub> to reset the system (Rouillon et al., 2018), and demonstrated that viruses can subvert type III CRISPR immunity by means of a potent anti-CRISPR ring nuclease variant AcrIII-1. Here, we present a comprehensive analysis of the dynamic interplay between these enzymes, governing cyclic nucleotide levels and infection outcomes in virus-host conflict.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>CRISPR</kwd><kwd><italic>Sulfolobus solfataricus</italic></kwd><kwd>cyclic oligoadenylate</kwd><kwd>ribonuclease</kwd><kwd>ring nuclease</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>E. coli</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/S000313/1</award-id><principal-award-recipient><name><surname>White</surname><given-names>Malcolm F</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>210486/Z/18/Z</award-id><principal-award-recipient><name><surname>Czekster</surname><given-names>Clarissa M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The dynamic interplay between type III CRISPR enzymes governs cyclic nucleotide levels and infection outcomes in virus-host conflict.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>CRISPR systems are widespread in archaea and bacteria, providing adaptive immunity against invading mobile genetic elements (MGE) (<xref ref-type="bibr" rid="bib39">Sorek et al., 2013</xref>; <xref ref-type="bibr" rid="bib29">Makarova et al., 2020</xref>). Type III CRISPR systems (<xref ref-type="fig" rid="fig1">Figure 1</xref>) are multi-functional effector proteins that have specialised in the detection of foreign RNA (<xref ref-type="bibr" rid="bib41">Tamulaitis et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Zhu et al., 2018</xref>). The large subunit, Cas10, harbours two enzyme active sites that are activated by target RNA binding: a DNA-cleaving HD nuclease domain (<xref ref-type="bibr" rid="bib38">Samai et al., 2015</xref>; <xref ref-type="bibr" rid="bib11">Elmore et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Estrella et al., 2016</xref>; <xref ref-type="bibr" rid="bib21">Kazlauskiene et al., 2016</xref>) and a cyclase domain for cyclic oligoadenylate (cOA) synthesis (<xref ref-type="bibr" rid="bib22">Kazlauskiene et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Niewoehner et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Rouillon et al., 2018</xref>). The third enzymatic activity of type III systems is situated in the Cas7 subunit of the complex, which cleaves bound RNA targets and in turn regulates Cas10 enzymatic activities (<xref ref-type="bibr" rid="bib40">Tamulaitis et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">Rouillon et al., 2018</xref>; <xref ref-type="bibr" rid="bib20">Johnson et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Nasef et al., 2019</xref>). The cyclase domain polymerises ATP into cOA species consisting of between 3 and 6 AMP subunits (denoted cA<sub>3</sub>, cA<sub>4</sub> etc.), in varying proportions (<xref ref-type="bibr" rid="bib22">Kazlauskiene et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Niewoehner et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Rouillon et al., 2018</xref>; <xref ref-type="bibr" rid="bib15">Grüschow et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Nasef et al., 2019</xref>). cOA second messengers activate CRISPR ancillary nucleases of the Csx1/Csm6, Can1 (CRISPR associated nuclease 1) and NucC families, which drive the immune response against MGEs (<xref ref-type="bibr" rid="bib22">Kazlauskiene et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Niewoehner et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Rouillon et al., 2018</xref>; <xref ref-type="bibr" rid="bib15">Grüschow et al., 2019</xref>; <xref ref-type="bibr" rid="bib25">Lau et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">McMahon et al., 2020</xref>). To date, cA<sub>4</sub> appears to be the most widely used signalling molecule by type III CRISPR systems (<xref ref-type="bibr" rid="bib15">Grüschow et al., 2019</xref>). The ribonuclease activity of Csx1/Csm6 is crucial for the clearance of MGEs (<xref ref-type="bibr" rid="bib16">Hatoum-Aslan et al., 2014</xref>; <xref ref-type="bibr" rid="bib13">Foster et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Grüschow et al., 2019</xref>), particularly when viral genes are transcribed late in infection, at low levels or mutated (<xref ref-type="bibr" rid="bib16">Hatoum-Aslan et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Jiang et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Rostøl and Marraffini, 2019</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cartoon of type III CRISPR cyclic nucleotide signalling and defence in <italic>Sulfolobus solfataricus</italic>.</title><p>The Cas10 subunit of the type III CRISPR complex synthesises cyclic tetra-adenylate (cA<sub>4</sub>) when viral RNA transcripts are detected. Target RNA cleavage shuts-off cA<sub>4</sub> synthesis. cA<sub>4</sub> binds to the CARF (CRISPR associated Rossmann Fold) domain of CRISPR ancillary nuclease Csx1 and allosterically activates its HEPN (Higher Eukaryotes and Prokaryotes Nucleotide binding) domain, which degrades RNA non-specifically within the cell. Extant cA<sub>4</sub> is degraded slowly by CRISPR ring nucleases (Crn1 family) which likely facilitate cell recovery after clearing the virus. Viral anti-CRISPR ring nucleases (AcrIII-1 family) degrade cA<sub>4</sub> rapidly to stop activation of ancillary defence enzymes such as Csx1 and supress antiviral immunity.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig1-v2.tif"/></fig><p>In our previous study, we demonstrated that the type III-D system from <italic>Sulfolobus solfataricus</italic> synthesises predominantly cA<sub>4,</sub> which activates the CRISPR ancillary ribonuclease Csx1. We examined the first regulatory step in cOA synthesis in detail and demonstrated that target RNA cleavage and dissociation from the complex shut-off cOA synthesis (<xref ref-type="bibr" rid="bib36">Rouillon et al., 2018</xref>). Since CRISPR ancillary nucleases degrade nucleic acids non-specifically, cellular as well as viral targets are destroyed. Collateral cleavage of self-transcripts by a Csm6 enzyme has previously been shown to result in cell growth arrest (<xref ref-type="bibr" rid="bib35">Rostøl and Marraffini, 2019</xref>). Therefore, in addition to regulating the synthesis of cOA, cells need a mechanism to remove extant cOA if they are to return to normal growth. To solve this problem, <italic>S. solfataricus</italic> encodes CRISPR-associated ring nuclease 1 (Crn1) family enzymes (<xref ref-type="bibr" rid="bib2">Athukoralage et al., 2018</xref>). Crn1 enzymes slowly degrade cA<sub>4</sub> to yield di-adenylate products incapable of activating Csx1. In other species Csm6 proteins have evolved catalytic CARF domains capable of degrading cA<sub>4</sub>, thereby acting as their own ‘off-switches’ to their RNase activity (<xref ref-type="bibr" rid="bib3">Athukoralage et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Jia et al., 2019</xref>). Unsurprisingly, archaeal viruses and bacteriophage have co-opted this regulatory strategy in order to subvert type III CRISPR defence. Many archaeal viruses and bacteriophage encode a ring nuclease anti-CRISPR (AcrIII-1), unrelated to Crn1, which neutralises the type III response by rapidly degrading cA<sub>4</sub> to prevent ancillary nuclease activation (<xref ref-type="bibr" rid="bib4">Athukoralage et al., 2020</xref>).</p><p>It is clear that the cA<sub>4</sub> antiviral second messenger is at the centre of a network of interactions that are crucial for effective type III CRISPR defence against MGE. Here, we show that detection of even a single molecule of invading RNA has the potential to generate a large signal amplification via synthesis of cA<sub>4</sub> that in turn activates the non-specific degradative ribonuclease Csx1. We explore how a cellular ring nuclease can return the cell to a basal state and how viruses can subvert the system. By quantifying and modelling the equilibria and reactions that take place in the arena of type III CRISPR defence, we build a comprehensive model of this dynamic, life or death process.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>While the control of cOA synthesis by target RNA binding and cleavage is now understood reasonably well, the full implications of cOA generation in a virally-infected cell are not. This requires a detailed knowledge of the levels of cOA produced, consequences for antiviral defence enzymes and the effects of cOA degrading enzymes from cellular and viral sources. These were the aims of our study.</p><sec id="s2-1"><title>Signal amplification on cA<sub>4</sub> production</title><p>We first investigated the extent of signal amplification that occurs in a cell from detection of a single viral RNA and generation of the cA<sub>4</sub> second messenger. Using the <italic>S. solfataricus</italic> type III-D CRISPR effector, we varied the concentration of target RNA and quantified the resultant cA<sub>4</sub> production. As previously observed (<xref ref-type="bibr" rid="bib36">Rouillon et al., 2018</xref>), increasing the target RNA concentration resulted in increased cA<sub>4</sub> production (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Quantification of the concentration of cA<sub>4</sub> generated was accomplished by using α-<sup>32</sup>P-ATP and quantification of products using a phosphorimager in comparison to standards (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). We observed that approximately 1000 molecules (980 ± 24) of cA<sub>4</sub> were generated per molecule of RNA, over a range of 10–100 nM target RNA (<xref ref-type="fig" rid="fig2">Figure 2</xref>). When a poorly-cleavable target RNA species containing phosphorothioates was used as the substrate, the amount of cA<sub>4</sub> generated increased approximately 3-fold (3100 ± 750, <xref ref-type="fig" rid="fig2">Figure 2</xref>), confirming the important role of RNA cleavage for deactivation of the cyclase domain (<xref ref-type="bibr" rid="bib36">Rouillon et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Nasef et al., 2019</xref>). Additionally, analysis of previously published data enabled us to determine the catalytic rate constant (<italic>k</italic>) of cA<sub>4</sub> synthesis by the <italic>S. solfataricus</italic> type III effector as 0.04 ± 0.01 min<sup>−1</sup> at 70°C (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Approximately 1000 molecules cA<sub>4</sub> are made per molecule of RNA target.</title><p>(<bold>A</bold>) Upper panel shows phosphorimages of thin-layer chromatography of cyclic tetra-adenylate (cA<sub>4</sub>) made by <italic>S. solfataricus</italic> (Sso) Csm complex (470 nM carrying the CRISPR RNA A26) across a range of RNA target concentrations (0.1, 1, 10, 25,100 nM) complementary to the A26 CRISPR RNA at 70°C. Lower panel shows cA<sub>4</sub> synthesised with a cleavage resistant (phosphorothioate) form of the RNA target. (<bold>B</bold>) Bar graph of the concentration of cA<sub>4</sub> generated with increasing cleavable and cleavage-resistant RNA target generated by quantifying the densiometric signals from A, with an α-<sup>32</sup>P-ATP standard curve (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Error bars indicate the standard deviation of the mean of three technical replicates, with individual data points shown as clear circles. No data are shown for 1 nM cleavable RNA target as cA<sub>4</sub> generated was below detection limits. (<bold>C</bold>) Bar chart quantifying the number of molecules of cA<sub>4</sub> generated per molecule of cleavable or cleavage resistant target RNA across a range of RNA target concentrations. On average SsoCsm synthesised 980 ± 24 and 3100 ± 750 molecules of cA<sub>4</sub> per molecule of cleavable and cleavage resistant target RNA, respectively. (<bold>D</bold>) Cartoon depicting the cellular implications of ~1000 molecules of cA<sub>4</sub> generated per molecule of RNA target, which in <italic>S. solfataricus</italic> would equate to ~6 µM cA<sub>4</sub> within the cell.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Excel spreadsheet with raw data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55852-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Example of ATP standard curve used to determine the concentration of ATP converted to cyclic tetra-adenylate (cA<sub>4</sub>).</title><p>Left-hand side panel shows duplicate serial dilution of <sup>32</sup>P-α-ATP (5 nM) and ATP (500 µM) mix spotted (1 µl) on a thin-layer chromatography (TLC) plate. The right-hand side panel is a plot of the densiometric signal quantified from the TLC plate after phosphorimaging. The mean densiometric signal is plotted and errors bars showing the standard deviation are plotted but not visible due to their scale. The densiometric signal corresponding to cA<sub>4</sub> was compared to the standard curve to determine the concentration of ATP converted. Duplicate standard curves were carried out for each replicate assay examining cA<sub>4</sub> synthesis.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Rate of cA<sub>4</sub> synthesis by <italic>S. solfataricus</italic> type III-D effector complex.</title><p>Plot showing the concentration of cA<sub>4</sub> generated by SsoCsm (~4.2 µM) over time in the presence of 25 nM RNA target, 0.5 mM ATP and 2 nM <sup>32</sup>P-α-ATP at 70°C. The data were originally reported in <xref ref-type="bibr" rid="bib36">Rouillon et al. (2018)</xref> and here were fitted to an exponential equation to determine the kinetic rate constant of cA<sub>4</sub> synthesis (0.04 ± 0.01 min<sup>−1</sup>). Error bars show the standard deviation of the mean of three technical replicates.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Excel speadsheet with raw data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55852-fig2-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig2-figsupp2-v2.tif"/></fig></fig-group><p>Given that <italic>S. solfataricus</italic> cells are cocci with a diameter of approximately 0.7 µm, the volume of an average cell can be calculated as approximately 0.3 fL (by comparison, <italic>E. coli</italic> has a cell volume of 1 fL [<xref ref-type="bibr" rid="bib23">Kubitschek and Friske, 1986</xref>]). Using Avogadro’s number, 1000 molecules equates to an intracellular concentration of 6 µM cA<sub>4</sub> in <italic>S. solfataricus</italic>. Thus, detection of one viral RNA in the cell could result in the synthesis of 6 µM cA<sub>4</sub>, 10 RNAs – 60 µM, etc. The upper limits of cA<sub>4</sub> generation could be defined by the number of viral target RNAs present, the number of type III effectors carrying a crRNA matching that target, or even conceivably the amount of ATP available for cA<sub>4</sub> generation.</p></sec><sec id="s2-2"><title>Kinetic parameters of the Csx1 ribonuclease</title><p>The cA<sub>4</sub> second messenger binds to CARF family proteins to elicit an immune response. To understand the concentration of cA<sub>4</sub> required to activate an antiviral response, we determined the dissociation constant of the major ancillary ribonuclease Csx1 for the cA<sub>4</sub> activator. Using radioactive cA<sub>4</sub>, we titrated an increasing concentration of Csx1 protein and subjected the mixture to native gel electrophoresis (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>). cA<sub>4</sub> was bound by Csx1 with a dissociation constant (<italic>K</italic><sub>D</sub>) of 130 ± 20 nM. Thus, even one viral target RNA detected by the type III CRISPR system should generate enough cA<sub>4</sub> (6 µM) to fully activate the Csx1 ribonuclease for defence. We proceeded to estimate the binding affinity of a ribonuclease-deficient Csx1 variant for its RNA target, yielding an apparent dissociation constant of approximately 5 µM (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Finally, we measured the initial velocity of RNA degradation at a variety of RNA concentrations under steady state conditions and determined the multiple-turnover kinetic constant (<italic>k</italic><sub>cat</sub>) for cA<sub>4</sub>-activated RNA cleavage by Csx1 as 0.44 ± 0.03 min<sup>−1</sup> at 70°C (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Csx1 binds cA<sub>4</sub> with high affinity and RNA with relatively low affinity.</title><p>(<bold>A</bold>) Phosphorimage of native gel electrophoresis visualising cA<sub>4</sub> (20 nM) binding by Csx1 (concentrations as indicated in the figure). The other bands visible are due to unreacted ATP and other linear nucleotide products. (<bold>B</bold>) Plot of fraction of cA<sub>4</sub> bound by Csx1. Error bars indicate the standard deviation of the mean of four technical replicates and the data were fitted to a quadratic equation incorporating a term for non-specific binding. The inset plot is a magnification of cA<sub>4</sub> binding between 0.01 and 5 µM Csx1 dimer concentrations. (<bold>C</bold>) Phosphorimage of native gel electrophoresis visualising A1 substrate RNA binding by Csx1 H345N protein dimer in the absence (left hand-side) or presence (right hand-side) of unlabelled cA<sub>4</sub> (20 µM). The image shown is representative of three technical replicates. Control c – RNA alone.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Csx1 binding to cA<sub>4</sub> and RNA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55852-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig3-v2.tif"/></fig><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Degradation of RNA by Csx1.</title><p>Analysis of multiple-turnover, steady state kinetics of A1 RNA cleavage by Csx1 (125 nM dimer) at 70°C. The data were fitted to the Michaelis-Menten equation and error bars show the standard deviation of the mean of three technical replicates.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Excel spreadsheet with data for kinetics of Csx1.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55852-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig4-v2.tif"/></fig></sec><sec id="s2-3"><title>Kinetic and equilibrium constants of the ring nucleases Crn1 and AcrIII-1</title><p>We have previously established that Crn1 cleaved cA<sub>4</sub> at a rate of 0.089 ± 0.003 min<sup>−1</sup> at 50°C, while AcrIII-1 cleaved cA<sub>4</sub> at a rate of 5.4 ± 0.38 min<sup>−1</sup>, about 60-fold faster (<xref ref-type="bibr" rid="bib4">Athukoralage et al., 2020</xref>). The difference in reaction rates probably reflects the different roles of the two enzymes, with Crn1 working in conjunction with the type III CRISPR defence and AcrIII-1 opposing it. To quantify the interaction between ring nucleases and cA<sub>4</sub>, we titrated radioactively labelled cA<sub>4</sub> with either Crn1 or AcrIII-1 and visualised cA<sub>4</sub> binding by phosphorimaging following native gel electrophoresis. Crn1 bound cA<sub>4</sub> with an apparent <italic>K<sub>D</sub></italic> of ~50 nM, while the inactive H47A variant of AcrIII-1 bound cA<sub>4</sub> with an apparent <italic>K</italic><sub>D</sub> of ~25 nM (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Thus, both ring nucleases bound cA<sub>4</sub> three to four-fold more tightly than Csx1.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Crn1 and AcrIII-1 bind cA<sub>4</sub> with high affinity.</title><p>Phosphorimages of native gel electrophoresis visualising radiolabelled cyclic oligoadenylate (cOA) binding by (<bold>A</bold>) Crn1 (<bold>B</bold>) and catalytically inactive AcrIII-1 (SIRV1 gp29 H47A). Crn1 binds cA<sub>4</sub> (10 nM) with an apparent dissociation constant (<italic>K</italic><sub>D</sub>) of ~50 nM, whereas AcrIII-1 binds cA<sub>4</sub> with an apparent <italic>K</italic><sub>D</sub> of ~25 nM. The images shown are representative of three technical replicates. Control c – cOA alone. The other bands near the bottom of the gel are caused by unreacted ATP and other linear products.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig5-v2.tif"/></fig></sec><sec id="s2-4"><title>Kinetic modelling of the antiviral signalling pathway and its regulation by cA<sub>4</sub> degrading enzymes</title><p>We entered the experimentally determined kinetic and equilibria parameters into the KinTek Global Kinetic Explorer software package and generated a model to simulate RNA degradation by Csx1 and the effects of ring nucleases over time (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Enzyme concentrations were set initially at 1 µM, based on published studies of transcript levels (<xref ref-type="bibr" rid="bib34">Ortmann et al., 2008</xref>; <xref ref-type="bibr" rid="bib44">Wurtzel et al., 2010</xref>), but were varied during modelling to assess the influence of enzyme concentration on RNA cleavage. We standardised the reaction temperature at 70°C, close to the growth temperature of <italic>S. solfataricus</italic>. This necessitated an estimation of the rate constants of Crn1 and AcrIII-1, which were measured at lower temperatures, based on a 2-fold increase in activity for each 10°C rise in temperature, in line with our previous studies of these enzymes (<xref ref-type="bibr" rid="bib2">Athukoralage et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Athukoralage et al., 2020</xref>). To model the generation of cA<sub>4</sub> by the Csm:target RNA complex, we set the concentration of that complex at 6, 60 or 600 µM (equivalent to low, medium and high levels of infection), allowing the generation of the equivalent concentration of cA<sub>4</sub> with the measured rate constant of 0.04 min<sup>−1</sup> (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Henceforth, this will be referred to as 6, 60 or 600 µM cA<sub>4</sub> for simplicity.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Modelling of <italic>S. solfataricus</italic> antiviral signalling.</title><p>(<bold>A</bold>) Schematic showing kinetic and equilibrium parameters inserted into the KinTek Global Kinetic Explorer software for modelling the type III CRISPR defence illustrated in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Parameters have been determined in this study with the following exceptions: Crn1 rate constant of 0.46 min<sup>−1</sup> at 70°C estimated from rate of 0.23 min<sup>−1</sup> measured at 60°C and AcrIII-1 rate constant of 21.6 min<sup>−1</sup> at 70°C estimated from rate of 5.4 min<sup>−1</sup> measured at 50°C (<xref ref-type="bibr" rid="bib4">Athukoralage et al., 2020</xref>). The parameter ‘target-Csm-ATP’ was set at 6, 60 or 600 µM in simulations. Underscores connecting two variables indicate their relationship in a complex. cA<sub>4</sub>, cyclic tetra-adenylate; Crn1, CRISPR ring nuclease 1; AcrIII-1, viral ring nuclease anti-CRISPR SIRV1 gp29; Csx1, CRISPR ancillary ribonuclease; A<sub>2</sub> &gt;P, di-adenylate containing 2’,3’ cyclic phosphate (product of cA<sub>4</sub> cleavage). (<bold>B</bold>) Free cA<sub>4</sub> (600 µM, blue; 60 µM, red; 6 µM, green) concentration and (<bold>C</bold>), RNA cleavage in presence of 1 µM Crn1 and 1 µM Csx1. (<bold>D</bold>) and (<bold>E</bold>) show equivalent plots in the presence of 1 µM AcrIII-1. Insets where present show a magnified view of the start of each plot. (<bold>F</bold>) 3D plot visualising concentration of RNA (1000 µM at start) cleaved by Csx1 in response to 60 µM cA<sub>4</sub> made by Csm complex, 1 µM Crn1 and varying amounts of AcrIII-1 across a range of doubling endpoints. (<bold>G</bold>) 3D plot visualising concentration of RNA (1000 µM at start) cleaved by Csx1 in response to 60 µM cA<sub>4</sub> made by Csm complex, and varying concentrations of Csx1, Crn1 and AcrIII-1 enzymes.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw data from modelling.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55852-fig6-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Extracted data from modelling.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55852-fig6-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6scode1"><label>Figure 6—source code 1.</label><caption><title>KinTek model code for kinetic modelling in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-55852-fig6-code1-v2.mec.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Modelling of RNA cleavage by Csx1 stimulated by cA<sub>4</sub> synthesised in response to varying target RNA concentrations.</title><p>Plot of RNA (1000 µM) cleaved by 1 µM Csx1 in the presence of 6, 60 or 600 µM cA<sub>4</sub> and no ring nuclease. Identical amounts of RNA are cleaved when cA<sub>4</sub> synthesised is in excess of Csx1 concentration and all the RNA present is eventually degraded.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Modelling of the relationship between Csx1 RNA cleavage and deactivation by ring nucleases with varying cA<sub>4</sub> concentrations.</title><p>(<bold>A</bold>) Active fraction of 1 µM Csx1 (dotted lines, left-hand side y-axis; cA<sub>4</sub>_Csx1 and cA<sub>4</sub>_Csx1_RNA) plotted together with cleaved RNA (solid lines, right-hand side axis) in response to varying cA<sub>4</sub> concentrations (600 µM, blue; 60 µM, red; 6 µM, green) made by target:Csm complex when 1 µM Crn1 is present. (<bold>B</bold>) Active fraction of 1 µM Csx1 and cleaved RNA over time in response to varying cA<sub>4</sub> concentrations when 1 µM Crn1 and 1 µM AcrIII-1 is present, as colour coded previously.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig6-figsupp2-v2.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Modelling of the effect of varying AcrIII-1 concentration on RNA cleaved by Csx1 in response to cA<sub>4</sub> generated by 600 µM target RNA.</title><p>3D plot visualising concentration of RNA (1000 µM at start) cleaved by Csx1 in the presence of 600 µM cA<sub>4</sub>, 1 µM Crn1 and varying amounts of AcrIII-1 over time. Maximal RNA cleavage negatively correlates with AcrIII-1 concentration.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-fig6-figsupp3-v2.tif"/></fig></fig-group><p>In the absence of any ring nuclease activity, 1 µM Csx1 was fully activated, degrading all 1000 µM RNA provided in the simulation within 2400 min, regardless of the simulated level of infection (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). The lack of titration of Csx1 activity observed here is due to its high affinity for cA<sub>4</sub>, resulting in full activation even at very low simulated infection levels. We observed a rapid initial increase in the levels of cA<sub>4</sub> due to synthesis by the activated Csm complex (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). In the simulations, 1 µM Crn1 degraded 60 µM cA<sub>4</sub> within 120 min, but took over 1200 min to degrade 600 µM cA<sub>4</sub> (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). These differences were reflected in the levels of Csx1-mediated RNA degradation, which were much higher for 600 µM cA<sub>4</sub> than for the lower concentrations (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Thus, the kinetic modelling demonstrated that addition of a ring nuclease activity allows the cell to respond differently to varied levels of infection, and therefore cA<sub>4</sub> concentration, resulting in a range of RNA degradation levels.</p><p>We next introduced the AcrIII-1 enzyme to the simulation, to model the effect of the Acr on the host defence system. Strikingly, when AcrIII-1 was present at 1 µM, even 600 µM cA<sub>4</sub> was degraded rapidly (the bulk within 10 min). As a result, Csx1 activity and therefore RNA degradation were strongly supressed (<xref ref-type="fig" rid="fig6">Figure 6D,E</xref>). The long tail of cA<sub>4</sub> observed in these simulations represents cA<sub>4</sub> bound to the Csx1 enzyme and thus unavailable for degradation by AcrIII-1, reflected in the persistence of active Csx1-cA<sub>4</sub> complex in the simulations over an extended period (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). Notably, at the highest simulated infection level of 600 µM cA<sub>4</sub>, Csx1 persists in a 100% activated form for over 1200 min in the absence of AcrIII-1, but is reduced to 50% activated within 150 min in its presence, with similar effects seen at lower cA<sub>4</sub> concentrations (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>).</p><p>The concentration of AcrIII-1 within <italic>S. solfataricus</italic> cells during infection is not known. We therefore varied AcrIII-1 concentration in the model (with 60 µM cA<sub>4</sub>, 1 µM Csx1 and Crn1) and simulated RNA cleavage (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). AcrIII-1 concentrations as low as 100 nM reduced RNA cleavage by about 30%, and higher levels reduced RNA cleavage by Csx1 markedly (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). This relationship held in simulations with 600 µM cA<sub>4</sub> (<xref ref-type="fig" rid="fig6">Figure 6F</xref>, <xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3</xref>). During infection, a positive correlation between AcrIII-1 concentration and viral transcript levels would be required for continued escape from Csx1-mediated CRISPR defence – a reasonable assumption. Finally, we simulated the effects of increasing Csx1 on RNA cleavage in our infection model. Increasing Csx1 concentration 10-fold led to a significantly more robust immune response (reflected in high levels of RNA degradation) (<xref ref-type="fig" rid="fig6">Figure 6G</xref>) that could not be fully overcome by increasing the concentrations of Crn1 or AcrIII-1 in proportion (compare for example 10,10,10 with 1,1,1 µM in <xref ref-type="fig" rid="fig6">Figure 6G</xref>). Hence, increasing the expression levels of defence nucleases such as Csx1 in response to viral infection could provide an effective means for cells to combat viruses armed with Acrs such as AcrIII-1, but perhaps with the cost of increased toxicity.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>Signal amplification in type III CRISPR defence</title><p>In this study, we used biochemical data to build a kinetic model of the type III CRISPR antiviral signalling pathway within <italic>S. solfataricus</italic> cells and examined the capacity of CRISPR and anti-CRISPR ring nucleases for its regulation. Quantification of cA<sub>4</sub> generated by the SsoCsm complex in vitro revealed that ~ 1000 molecules of cA<sub>4</sub> are made per RNA target, amounting to a concentration of 6 µM in the cell if replicated in vivo. This large degree of signal amplification would ensure that detection of 1 RNA target could generate sufficient amounts of cA<sub>4</sub> to fully activate the ribonuclease effector protein Csx1, which has a dissociation constant for cA<sub>4</sub> of 0.13 µM. Given the large signal amplification observed here, it seems likely that some means of cOA degradation, either via self-limiting ribonucleases (<xref ref-type="bibr" rid="bib3">Athukoralage et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Jia et al., 2019</xref>) or dedicated ring nucleases (<xref ref-type="bibr" rid="bib2">Athukoralage et al., 2018</xref>), will be essential for type III CRISPR systems to provide immunity rather than elicit abortive infection. Indeed, growth arrest has been observed for cOA activated Csm6 during bacteriophage infection (<xref ref-type="bibr" rid="bib35">Rostøl and Marraffini, 2019</xref>). This life or death decision in response to genotoxic stress has also been observed in <italic>S. islandicus</italic>, which becomes dormant upon viral infection and subsequently dies if virus remains in culture (<xref ref-type="bibr" rid="bib5">Bautista et al., 2015</xref>). In recent years, diverse CRISPR systems have been implicated in abortive infection or cell dormancy. The Type I-F CRISPR system of <italic>Pectobacterium atrosepticum</italic> was found to provide population protection by aborting infection when infected by virulent phage (<xref ref-type="bibr" rid="bib42">Watson et al., 2019</xref>). Likewise, the in-trans collateral RNA cleavage of <italic>Listeria seeligeri</italic> Cas13a resulted in cell dormancy, providing herd immunity to the bacterial population (<xref ref-type="bibr" rid="bib31">Meeske et al., 2019</xref>). Similarly, in ecological contexts, it is possible that different multiplicities of viral infection illicit different outcomes from the type III CRISPR response that benefit either the individual cell or the population.</p></sec><sec id="s3-2"><title>Cellular and viral ring nucleases reset the system in fundamentally different ways</title><p>Biochemical comparison of Crn1 and AcrIII-1 revealed that both enzymes bind cA<sub>4</sub> with dissociation constants around 40 nM, around 3-fold tighter than observed for Csx1. However, Crn1 is a much slower enzyme. Kinetic modelling of the antiviral signalling pathway confirms that Crn1 is effective only at low levels of viral gene expression, where it has the potential to neutralise the toxicity associated with cA<sub>4-</sub>activated ribonucleases to offer a route for cell recovery without abrogating immunity. In contrast, the much faster reaction kinetics of the anti-CRISPR ring nuclease means it can rapidly deactivate Csx1 and immunosuppress cells even under very high RNA target (and thus cA<sub>4</sub>) levels.</p><p>Our modelling suggests that the rapid turnover of cA<sub>4</sub> by AcrIII-1 over a wide concentration range greatly limits RNA cleavage by deactivating defence enzymes. Therefore, the deployment of AcrIII-1 upon viral infection may not only promote viral propagation but also safeguard cellular integrity until viral release by lysis. Recent studies have uncovered that sequentially infecting phage evade CRISPR defences by exploiting the immunosuppression achieved by Acr enzymes from failed infections (<xref ref-type="bibr" rid="bib6">Borges et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Landsberger et al., 2018</xref>). Further, these immunosuppressed cells have been shown to be susceptible to Acr-negative phage infections, highlighting the complex ecological consequences of supressing CRISPR immunity (<xref ref-type="bibr" rid="bib8">Chevallereau et al., 2020</xref>). In <italic>Sulfolobus</italic> Turreted Icosahedral virus (STIV), the AcrIII-1 gene <italic>B116</italic> is expressed early in the viral life cycle (<xref ref-type="bibr" rid="bib34">Ortmann et al., 2008</xref>). Therefore, AcrIII-1 accumulation in the cell, possibly from early expression by unsuccessful viruses may, as our models demonstrate, favour the success of latter viral infections. Type III CRISPR systems also conditionally tolerate prophage (<xref ref-type="bibr" rid="bib14">Goldberg et al., 2014</xref>), and unsurprisingly, AcrIII-1 is found in a number of prophages and integrative and conjugative elements. In these cases, constitutively expressed AcrIII-1 may further immunocompromise cells, and sensitise them to infection by phage otherwise eradicated by type III CRISPR defence. In the ongoing virus-host conflict, while increasing Csx1 concentration may allow better immunity when faced with AcrIII-1, upregulating AcrIII-1 expression in cells will undoubtedly offer viruses an avenue for counter offence.</p><p>It should be noted that the type III CRISPR locus of <italic>S. solfataricus</italic> contains a number of CARF domain proteins and their contribution to immunity has not yet been studied. In particular, the CARF-family putative transcription factor Csa3 appears to be involved in transcriptional regulation of CRISPR loci, including the adaptation and type I-A effector genes, when activated by cA<sub>4</sub> (<xref ref-type="bibr" rid="bib27">Liu et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Liu et al., 2017</xref>). These observations suggest that the cA<sub>4</sub> signal may transcend type III CRISPR defence in some cell types by activating multiple defence systems. However, by degrading the second messenger, AcrIII-1 has the potential to neutralise all of these.</p></sec><sec id="s3-3"><title>Cyclic nucleotides in prokaryotic defence systems</title><p>Cyclic nucleotide-based defence systems are emerging as powerful cellular sentinels against parasitic elements in prokaryotes. Mirroring the role of cyclic GMP-AMP synthase (cGAS) in eukaryotic defence against viruses as part of the cGAS-STING pathway, bacterial cGAS enzymes have recently been discovered that abort infection by activating phospholipases through cGAMP signaling (<xref ref-type="bibr" rid="bib9">Cohen et al., 2019</xref>). Termed the cyclic-oligonucleotide-based antiphage signaling system (CBASS), a large number of additional cOA sensing effector proteins associated with CBASS loci remain uncharacterised, highlighting great diversity in the cellular arsenal used for defence (<xref ref-type="bibr" rid="bib7">Burroughs et al., 2015</xref>; <xref ref-type="bibr" rid="bib9">Cohen et al., 2019</xref>). Furthermore, diverse nucleotide cyclases have been identified that generate a range of cyclic nucleotides including cUMP-AMP, c-di-UMP and cAAG, which are also likely to function in novel antiviral signal transduction pathways (<xref ref-type="bibr" rid="bib43">Whiteley et al., 2019</xref>). Type III systems also generate cyclic tri-adenylate (cA<sub>3</sub>) and cyclic penta-adenylate (cA<sub>5</sub>) molecules. Whereas no signalling role has yet been ascribed to cA<sub>5</sub>, cA<sub>3</sub> has been demonstrated to activate a family of DNases termed NucC which abort infection by degrading the host genome prior to completion of the phage replication cycle (<xref ref-type="bibr" rid="bib25">Lau et al., 2020</xref>).</p><p>The balance between immunity, abortive infection and successful pathogen replication is likely to be governed by enzymes that synthesise and degrade these cyclic nucleotide second messengers. Just as prokaryotes with type III CRISPR require a means to degrade cOA in appropriate circumstances, eukaryotic cells have enzymes that degrade cGAMP to regulate cGAS-STING mediated immunity (<xref ref-type="bibr" rid="bib26">Li et al., 2014</xref>). Likewise, while prokaryotic viruses utilise AcrIII-1 to rapidly degrade cA<sub>4</sub>, eukaryotic poxviruses utilise Poxins to subvert host immunity by destroying cGAMP (<xref ref-type="bibr" rid="bib10">Eaglesham et al., 2019</xref>), and pathogenic Group B <italic>Streptococci</italic> degrade host c-di-AMP using the CndP enzyme to circumvent innate immunity (<xref ref-type="bibr" rid="bib1">Andrade et al., 2016</xref>). The rate of discovery of new defence pathways and cyclic nucleotide signals is breath-taking. Analysis of the dynamic interplay between enzymes that leads to fluctuations in the levels of these second messengers is therefore of crucial importance if we are to achieve an understanding of these processes.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Gene (<italic>Sulfolobus solfataricus</italic>)</td><td valign="top">Csm complex (eight subunits)</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/24119402">24119402</ext-link></td><td valign="top"/><td valign="top">virus expression construct</td></tr><tr><td valign="top">Gene <break/>(<italic>Sulfolobus solfataricus</italic>)</td><td valign="top">Csx1</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/29963983">29963983</ext-link></td><td valign="top">UniProtKB - Q97YD5</td><td valign="top">plasmid expression construct</td></tr><tr><td valign="top">Gene (<italic>Sulfolobus solfataricus</italic>)</td><td valign="top">Crn1</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/30232454">30232454</ext-link></td><td valign="top">UniProtKB - Q7LYJ6</td><td valign="top">plasmid expression construct</td></tr><tr><td valign="top">Gene (<italic>Sulfolobus islandicus rod-shaped virus 1</italic>)</td><td valign="top">AcrIII-1</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/31942067">31942067</ext-link></td><td valign="top">UniProtKB - Q8QL27</td><td valign="top">plasmid expression construct</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">KinTek <break/>Kinetic Explorer</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/19897109">19897109</ext-link></td><td valign="top"/><td valign="top">model constructed <break/>for this paper</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cyclic oligoadenylate (cOA) synthesis and visualisation</title><p>Cyclic tetra-adenylate (cA<sub>4</sub>) made per RNA target (0.01, 0.1, 1, 10, 25 or 50 nM) was investigated in a 20 μl reaction volume incubating A26 RNA target or A26 phosphorothioate RNA target (<xref ref-type="table" rid="table1">Table 1</xref>) with 13.5 μg <italic>Sulfolobus solfataricus</italic> (Sso)Csm complex (~470 nM carrying A26 CRISPR RNA) in Csx1 buffer containing 20 mM MES pH 5.5, 100 mM K-glutamate, 1 mM DTT and 3 units SUPERase•In Inhibitor supplemented with 1 mM ATP, 5 nM α-<sup>32</sup>P-ATP and 2 mM MgCl<sub>2</sub> at 70°C for 2 hr. All samples were deproteinised by phenol-chloroform extraction (Ambion) followed by chloroform (Sigma-Aldrich) extraction prior to separating the cOA products by thin-layer chromatography (TLC). TLC was carried out as previously described (<xref ref-type="bibr" rid="bib37">Rouillon et al., 2019</xref>). In brief, 1 μl of radiolabelled cOA product was spotted 1 cm from the bottom of a 20 × 20 cm silica gel TLC plate (Supelco Sigma-Aldrich). The TLC plate was placed in a sealed glass chamber pre-warmed at 37°C containing 0.5 cm of a running buffer composed of 30% H<sub>2</sub>O, 70% ethanol and 0.2 M ammonium bicarbonate, pH 9.2. After TLC the plate was air dried and sample migration visualised by phosphor imaging. For analysis, densiometric signals corresponding to cA<sub>4</sub> was quantified as previously described (<xref ref-type="bibr" rid="bib37">Rouillon et al., 2019</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Oligonucleotides.</title><p>CRISPR RNA A26 is shown 3’ to 5’. Phosphorothioate linkages are indicated with an asterisk. Regions complementary to CRISPR RNA A26 are italicized.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top">Crispr rna a26</td><td valign="top">3’-<named-content content-type="sequence">GCAACAATTCTTGCTGCAACAATCTTCAACCCATACCAGAAAGUUA</named-content></td></tr><tr><th valign="top">Name</th><th valign="top">Sequence (5’−3’)</th></tr><tr><td valign="top">Target RNA A26</td><td valign="top"><named-content content-type="sequence">AGGGUCGUUGUUAAGAACGACGUUGUUAGAAGUUGGGUAUGGUGGAGA</named-content></td></tr><tr><td valign="top">Phosphorothioate target RNA A26</td><td valign="top"><named-content content-type="sequence">AGGGUCGUUGUUAAGAACGACGUUGU</named-content><named-content content-type="sequence">*U*A*GAAGUUGGGU*A*U*GGUGGAGA</named-content></td></tr><tr><td valign="top">A1 substrate RNA</td><td valign="top"><named-content content-type="sequence">AGGGUAUUAUUUGUUUGUUUCUUCUAAACUAUAAGCUAGUUCUGGAGA</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s4-2"><title>Generation of α-<sup>32</sup>P-ATP standard curves</title><p>cA<sub>4</sub> synthesis was visualised by incorporation of 5 nM α-<sup>32</sup>P-ATP added together with 0.5 mM ATP at the start of the reaction. Therefore, to calculate the concentration of ATP used for cA<sub>4</sub> synthesis, α-<sup>32</sup>P-ATP standard curves were generated in duplicate, starting with 5 nM α-<sup>32</sup>P-ATP within a 20 μl volume to represent the densiometric signal corresponding to the complete conversion of 0.5 mM ATP into cOA. Serial two-fold dilutions of 5 nM α-<sup>32</sup>P-ATP and 0.5 mM ATP starting from a 20 μl volume were made and 1 μl of each dilution was spotted on a silica plate and phosphorimaged alongside TLC separating cOA made with varying RNA target concentrations. After phosphorimaging, the densiometric signals of the serial dilutions were quantified, averaged and plotted against ATP concentration starting from 0.5 mM and halving with each two-fold dilution. A line of best fit was then drawn. The concentration of ATP used to synthesise cA<sub>4</sub> was calculated by entering the densiometric signal of the cA<sub>4</sub> product into to equation of the line of best fit for the α-<sup>32</sup>P-ATP standard curve. The concentration of cA<sub>4</sub> generated was derived by dividing the concentration of ATP incorporated by four to account for polymerisation of four ATP molecules to generate one molecule of cA<sub>4</sub>. Finally, the molecules of cA<sub>4</sub> made per RNA was calculated by dividing the cA<sub>4</sub> concentration generated by the concentration A26 RNA target used for cOA synthesis.</p><p>Calculation determining the concentration of cA<sub>4</sub> made when one RNA target is detected within a <italic>S. solfataricus</italic> cell of ≈ 0.8 µm (0.6–1.0 µm) diameter.<disp-formula id="equ1"><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">u</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mtext> </mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>V</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>4</mml:mn><mml:mn>3</mml:mn></mml:mfrac><mml:mi>π</mml:mi><mml:msup><mml:mi>r</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mi>d</mml:mi></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ2"><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mtext> </mml:mtext><mml:mo>×</mml:mo><mml:mtext> </mml:mtext><mml:mn>0.8</mml:mn><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi>μ</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ3"><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>0.4</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>μ</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ4"><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>4</mml:mn><mml:mn>3</mml:mn></mml:mfrac><mml:mi>π</mml:mi><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>0.4</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>μ</mml:mi><mml:mi>m</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ5"><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mn>0.268</mml:mn><mml:msup><mml:mrow><mml:mspace width="thinmathspace"/><mml:mi>μ</mml:mi><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ6"><mml:math id="m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mspace width="thinmathspace"/><mml:msup><mml:mrow><mml:mi>μ</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ7"><mml:math id="m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0.268</mml:mn><mml:msup><mml:mrow><mml:mspace width="thinmathspace"/><mml:mi>μ</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.268</mml:mn><mml:mrow><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mn>2.68</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>13</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ8"><mml:math id="m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mo>=</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mn>6.022</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mn>23</mml:mn></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ9"><mml:math id="m9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>÷</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mn>6.022</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mn>23</mml:mn></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mo>=</mml:mo><mml:mn>1.661</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>24</mml:mn></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>As ~1000 molecules of cA<sub>4</sub> is made per 1 molecule of RNA<disp-formula id="equ10"><mml:math id="m10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1.661</mml:mn><mml:mtext> </mml:mtext><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>24</mml:mn><mml:mtext> </mml:mtext></mml:mrow></mml:msup><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mtext> </mml:mtext><mml:mo>×</mml:mo><mml:mtext> </mml:mtext><mml:mn>1000</mml:mn><mml:mtext> </mml:mtext><mml:mo>=</mml:mo><mml:mn>1.661</mml:mn><mml:mtext> </mml:mtext><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>21</mml:mn></mml:mrow></mml:msup><mml:mtext> </mml:mtext><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>Concentration (M) = moles / Volume (L)<disp-formula id="equ11"><mml:math id="m11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1.661</mml:mn><mml:mtext> </mml:mtext><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>21</mml:mn></mml:mrow></mml:msup><mml:mtext> </mml:mtext><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mtext> </mml:mtext><mml:mo>÷</mml:mo><mml:mtext> </mml:mtext><mml:mn>2.68</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>16</mml:mn></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mn>6.20</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mspace width="thinmathspace"/><mml:mn>6.20</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">c</mml:mi><mml:msub><mml:mi mathvariant="normal">A</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula></p></sec><sec id="s4-3"><title>Electrophoretic mobility shift assays to determine cA<sub>4</sub> equilibrium binding constants</title><p>~20 nM radioactively-labelled cA<sub>4</sub> generated using the SsoCsm was incubated with increasing concentrations of Csx1 (0.01, 0.05, 0.10, 0.20, 0.40, 0.60, 0.80, 1,0, 2.0, 4.0, 8.0, 10.0, 20.0 μM protein dimer) in buffer containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM MgCl<sub>2</sub> supplemented with 2 µM Ultrapure Bovine Serum Albumin (Invitrogen) for 10 min at 25°C. A reaction volume equivalent of 20% (v/v) glycerol was then added prior to loading the samples on a 15% polyacrylamide, 1 X TBE gel. Electrophoresis was carried out at 28°C and 250 V. Gels were phosphor imaged overnight at −80°C. For investigating RNA binding, 50 nM 5’-end radiolabelled and gel purified A1 RNA was incubated with Csx1 variant H345N (0.01, 0.10, 1.0, 5.0, 10.0, 20.0 μM protein dimer) in the presence or absence of 20 µM cA<sub>4</sub> for 15 min at 40°C. To examine cA<sub>4</sub> binding by Crn1,~10 nM radiolabelled SsoCsm cA<sub>4</sub> was incubated with Sso2081 (0.01, 0.05, 0.10, 0.20, 0.40, 0.60, 0.80, 1,0, 2.0, 4.0, 8.0, 10.0, 20.0 μM protein dimer) on ice for 15 min before gel electrophoresis as described above but at 300V and at 4°C. cA<sub>4</sub> binding by AcrIII-1 was examined by incubating ~10 nM radiolabelled SsoCsm cA<sub>4</sub> with SIRV1 gp49 H47A (0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.08, 0.10, 1.0, 10.0, 20.0 µM protein dimer) for 10 min at 25°C before gel electrophoresis at 30°C as described above. For analysis densiometric signal corresponding to cA<sub>4</sub> bound protein was quantified. The densiometric count corresponding to cA<sub>4</sub> bound to 20 µM Csx1 dimer was used to represent 100% binding and densiometric counts from other lanes were normalised to this value within each replicate. Error of the 100% bound (20 µM Csx1 dimer) densiometric count was derived by calculating the area adjusted count for each replicate and then the standard deviation of their mean, reporting the standard deviation as a fraction of the mean set as 100% bound. The data were fitted to a quadratic equation with an adjust for nonspecific binding (Y = (ymax-ymin)*((x + [ligand] + Kd) - ((x+[ligand]+Kd)^2–4*x*[ligand])^0.5)/(2*[ligand]) +a*x+b) using GraphPad Prism 8.</p></sec><sec id="s4-4"><title>Multiple turnover kinetics of RNA cleavage by Csx1</title><p>Multiple turnover kinetic experiments were carried out by incubating Csx1 (0.125 µM dimer) with radiolabelled (50 nM) and unlabelled RNA A1 to a final concentration of 1.25, 1.5, 2.0, 5.0, 10.0, or 20.0 μM RNA in Csx1 buffer at 70°C. Control reactions with no protein and with protein and RNA in the absence of cA<sub>4</sub> were included. 10 μl reaction aliquots were quenched by adding to phenol-chloroform and vortexing and the different time-points at which reactions were quenched for each RNA concentration is indicated in data transparency. Deproteinised products were run on a 7 M urea, 20% acrylamide, 1 X TBE gel at 45°C as previously described (<xref ref-type="bibr" rid="bib37">Rouillon et al., 2019</xref>), and phosphorimaged overnight at −80°C. Each experiment was carried out in triplicate. Fraction of RNA cut was plotted against time and a linear regression was carried out on the linear portion of each plot to determine the initial rate of RNA cleavage at each RNA concentration. To determine the parameters <italic>k</italic><sub>cat</sub> and <italic>K</italic><sub>M</sub>, the average initial rate of RNA cleavage was plotted against RNA concentration and fitted to the Michaelis-Menten equation using GraphPad Prism 8.</p></sec><sec id="s4-5"><title>Modelling antiviral signalling and its control by ring nucleases</title><p>Modelling was carried out using the KinTek Explorer eight software package (<xref ref-type="bibr" rid="bib19">Johnson, 2009</xref>), which is available from (<ext-link ext-link-type="uri" xlink:href="https://kintekcorp.com/software">https://kintekcorp.com/software</ext-link>). Experiments were modelled and simulated using kinetic and equilibrium paramters detemined experimentally as described in <xref ref-type="fig" rid="fig6">Figure 6A</xref>. The following steps were inserted to generate the model:</p><list list-type="simple"><list-item><p>target_Csm_ATP = target_Csm + cA4 (irreversible)</p></list-item><list-item><p>cA4 + Csx1 = cA4_Csx1</p></list-item><list-item><p>cA4_Csx1 + RNA = cA4_Csx1_RNA</p></list-item><list-item><p>cA4_Csx1_RNA = cA4_Csx1_cleavedRNA (irreversible)</p></list-item><list-item><p>cA4_Csx1_cleavedRNA = cA4_Csx1 + cleavedRNA</p></list-item><list-item><p>cA4 + Crn1 = cA4_Crn1</p></list-item><list-item><p>cA4_Crn1 = A2 + Crn1 (irreversible)</p></list-item><list-item><p>cA4 + Vrn = cA4_Vrn cA4_Vrn = A2 + Vrn (irreversible)</p></list-item></list><p>Simulations were carried out varying target_Csm_ATP concentration (6, 60 and 600 µM) while Csx1, Crn1 (Sso2081) and AcrIII-1 concentrations were fixed at 1 µM dimer, or varied depending on the simulation, with total substrate RNA in the cell fixed at 1000 µM.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by a grant from the Biotechnology and Biological Sciences Research Council (Grant REF BB/S000313/1 to MFW) and the Wellcome Trust (Grant 210486/Z/18/Z to CMC)</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-55852-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2, 3, 4 and 6.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname> <given-names>WA</given-names></name><name><surname>Firon</surname> <given-names>A</given-names></name><name><surname>Schmidt</surname> <given-names>T</given-names></name><name><surname>Hornung</surname> <given-names>V</given-names></name><name><surname>Fitzgerald</surname> <given-names>KA</given-names></name><name><surname>Kurt-Jones</surname> <given-names>EA</given-names></name><name><surname>Trieu-Cuot</surname> <given-names>P</given-names></name><name><surname>Golenbock</surname> <given-names>DT</given-names></name><name><surname>Kaminski</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Group B Streptococcus degrades Cyclic-di-AMP to modulate STING-Dependent type I interferon production</article-title><source>Cell Host &amp; Microbe</source><volume>20</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.06.003</pub-id><pub-id pub-id-type="pmid">27414497</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athukoralage</surname> <given-names>JS</given-names></name><name><surname>Rouillon</surname> <given-names>C</given-names></name><name><surname>Graham</surname> <given-names>S</given-names></name><name><surname>Grüschow</surname> <given-names>S</given-names></name><name><surname>White</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ring nucleases deactivate type III CRISPR ribonucleases by degrading cyclic oligoadenylate</article-title><source>Nature</source><volume>562</volume><fpage>277</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0557-5</pub-id><pub-id pub-id-type="pmid">30232454</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athukoralage</surname> <given-names>JS</given-names></name><name><surname>Graham</surname> <given-names>S</given-names></name><name><surname>Grüschow</surname> <given-names>S</given-names></name><name><surname>Rouillon</surname> <given-names>C</given-names></name><name><surname>White</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A type III CRISPR ancillary ribonuclease degrades its cyclic oligoadenylate activator</article-title><source>Journal of Molecular Biology</source><volume>431</volume><fpage>2894</fpage><lpage>2899</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.04.041</pub-id><pub-id pub-id-type="pmid">31071326</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athukoralage</surname> <given-names>JS</given-names></name><name><surname>McMahon</surname> <given-names>SA</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Grüschow</surname> <given-names>S</given-names></name><name><surname>Graham</surname> <given-names>S</given-names></name><name><surname>Krupovic</surname> <given-names>M</given-names></name><name><surname>Whitaker</surname> <given-names>RJ</given-names></name><name><surname>Gloster</surname> <given-names>TM</given-names></name><name><surname>White</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity</article-title><source>Nature</source><volume>577</volume><fpage>572</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1909-5</pub-id><pub-id pub-id-type="pmid">31942067</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bautista</surname> <given-names>MA</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Whitaker</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Virus-induced dormancy in the archaeon Sulfolobus islandicus</article-title><source>mBio</source><volume>6</volume><elocation-id>e02565</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02565-14</pub-id><pub-id pub-id-type="pmid">25827422</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borges</surname> <given-names>AL</given-names></name><name><surname>Zhang</surname> <given-names>JY</given-names></name><name><surname>Rollins</surname> <given-names>MF</given-names></name><name><surname>Osuna</surname> <given-names>BA</given-names></name><name><surname>Wiedenheft</surname> <given-names>B</given-names></name><name><surname>Bondy-Denomy</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Bacteriophage cooperation suppresses CRISPR-Cas3 and Cas9 immunity</article-title><source>Cell</source><volume>174</volume><fpage>917</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.06.013</pub-id><pub-id pub-id-type="pmid">30033364</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burroughs</surname> <given-names>AM</given-names></name><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Schäffer</surname> <given-names>DE</given-names></name><name><surname>Iyer</surname> <given-names>LM</given-names></name><name><surname>Aravind</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Comparative genomic analyses reveal a vast, novel network of nucleotide-centric systems in biological conflicts, immunity and signaling</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>10633</fpage><lpage>10654</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1267</pub-id><pub-id pub-id-type="pmid">26590262</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chevallereau</surname> <given-names>A</given-names></name><name><surname>Meaden</surname> <given-names>S</given-names></name><name><surname>Fradet</surname> <given-names>O</given-names></name><name><surname>Landsberger</surname> <given-names>M</given-names></name><name><surname>Maestri</surname> <given-names>A</given-names></name><name><surname>Biswas</surname> <given-names>A</given-names></name><name><surname>Gandon</surname> <given-names>S</given-names></name><name><surname>van Houte</surname> <given-names>S</given-names></name><name><surname>Westra</surname> <given-names>ER</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Exploitation of the cooperative behaviors of Anti-CRISPR phages</article-title><source>Cell Host &amp; Microbe</source><volume>27</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.12.004</pub-id><pub-id pub-id-type="pmid">31901522</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname> <given-names>D</given-names></name><name><surname>Melamed</surname> <given-names>S</given-names></name><name><surname>Millman</surname> <given-names>A</given-names></name><name><surname>Shulman</surname> <given-names>G</given-names></name><name><surname>Oppenheimer-Shaanan</surname> <given-names>Y</given-names></name><name><surname>Kacen</surname> <given-names>A</given-names></name><name><surname>Doron</surname> <given-names>S</given-names></name><name><surname>Amitai</surname> <given-names>G</given-names></name><name><surname>Sorek</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cyclic GMP-AMP signalling protects Bacteria against viral infection</article-title><source>Nature</source><volume>574</volume><fpage>691</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1605-5</pub-id><pub-id pub-id-type="pmid">31533127</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eaglesham</surname> <given-names>JB</given-names></name><name><surname>Pan</surname> <given-names>Y</given-names></name><name><surname>Kupper</surname> <given-names>TS</given-names></name><name><surname>Kranzusch</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS-STING signalling</article-title><source>Nature</source><volume>566</volume><fpage>259</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0928-6</pub-id><pub-id pub-id-type="pmid">30728498</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmore</surname> <given-names>JR</given-names></name><name><surname>Sheppard</surname> <given-names>NF</given-names></name><name><surname>Ramia</surname> <given-names>N</given-names></name><name><surname>Deighan</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Terns</surname> <given-names>RM</given-names></name><name><surname>Terns</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bipartite recognition of target RNAs activates DNA cleavage by the type III-B CRISPR-Cas system</article-title><source>Genes &amp; Development</source><volume>30</volume><fpage>447</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1101/gad.272153.115</pub-id><pub-id pub-id-type="pmid">26848045</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estrella</surname> <given-names>MA</given-names></name><name><surname>Kuo</surname> <given-names>FT</given-names></name><name><surname>Bailey</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RNA-activated DNA cleavage by the type III-B CRISPR-Cas effector complex</article-title><source>Genes &amp; Development</source><volume>30</volume><fpage>460</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1101/gad.273722.115</pub-id><pub-id pub-id-type="pmid">26848046</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname> <given-names>K</given-names></name><name><surname>Kalter</surname> <given-names>J</given-names></name><name><surname>Woodside</surname> <given-names>W</given-names></name><name><surname>Terns</surname> <given-names>RM</given-names></name><name><surname>Terns</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The ribonuclease activity of Csm6 is required for anti-plasmid immunity by type III-A CRISPR-Cas systems</article-title><source>RNA Biology</source><volume>16</volume><fpage>449</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1080/15476286.2018.1493334</pub-id><pub-id pub-id-type="pmid">29995577</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname> <given-names>GW</given-names></name><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Bikard</surname> <given-names>D</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting</article-title><source>Nature</source><volume>514</volume><fpage>633</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1038/nature13637</pub-id><pub-id pub-id-type="pmid">25174707</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grüschow</surname> <given-names>S</given-names></name><name><surname>Athukoralage</surname> <given-names>JS</given-names></name><name><surname>Graham</surname> <given-names>S</given-names></name><name><surname>Hoogeboom</surname> <given-names>T</given-names></name><name><surname>White</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>9259</fpage><lpage>9270</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz676</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatoum-Aslan</surname> <given-names>A</given-names></name><name><surname>Maniv</surname> <given-names>I</given-names></name><name><surname>Samai</surname> <given-names>P</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic characterization of antiplasmid immunity through a type III-A CRISPR-Cas system</article-title><source>Journal of Bacteriology</source><volume>196</volume><fpage>310</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1128/JB.01130-13</pub-id><pub-id pub-id-type="pmid">24187086</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname> <given-names>N</given-names></name><name><surname>Jones</surname> <given-names>R</given-names></name><name><surname>Yang</surname> <given-names>G</given-names></name><name><surname>Ouerfelli</surname> <given-names>O</given-names></name><name><surname>Patel</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CRISPR-Cas III-A Csm6 CARF domain is a ring nuclease triggering stepwise cA4 cleavage with ApA&gt;p formation terminating RNase activity</article-title><source>Molecular Cell</source><volume>75</volume><fpage>933</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.06.014</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Samai</surname> <given-names>P</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Degradation of phage transcripts by CRISPR-Associated RNases enables type III CRISPR-Cas immunity</article-title><source>Cell</source><volume>164</volume><fpage>710</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.12.053</pub-id><pub-id pub-id-type="pmid">26853474</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fitting enzyme kinetic data with KinTek global kinetic explorer</article-title><source>Methods in Enzymology</source><volume>467</volume><fpage>601</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(09)67023-3</pub-id><pub-id pub-id-type="pmid">19897109</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>K</given-names></name><name><surname>Learn</surname> <given-names>BA</given-names></name><name><surname>Estrella</surname> <given-names>MA</given-names></name><name><surname>Bailey</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Target sequence requirements of a type III-B CRISPR-Cas immune system</article-title><source>Journal of Biological Chemistry</source><volume>294</volume><fpage>10290</fpage><lpage>10299</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.008728</pub-id><pub-id pub-id-type="pmid">31110048</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazlauskiene</surname> <given-names>M</given-names></name><name><surname>Tamulaitis</surname> <given-names>G</given-names></name><name><surname>Kostiuk</surname> <given-names>G</given-names></name><name><surname>Venclovas</surname> <given-names>Č</given-names></name><name><surname>Siksnys</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Spatiotemporal control of type III-A CRISPR-Cas immunity: coupling DNA degradation with the target RNA recognition</article-title><source>Molecular Cell</source><volume>62</volume><fpage>295</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.03.024</pub-id><pub-id pub-id-type="pmid">27105119</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazlauskiene</surname> <given-names>M</given-names></name><name><surname>Kostiuk</surname> <given-names>G</given-names></name><name><surname>Venclovas</surname> <given-names>Č</given-names></name><name><surname>Tamulaitis</surname> <given-names>G</given-names></name><name><surname>Siksnys</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems</article-title><source>Science</source><volume>357</volume><fpage>605</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1126/science.aao0100</pub-id><pub-id pub-id-type="pmid">28663439</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubitschek</surname> <given-names>HE</given-names></name><name><surname>Friske</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Determination of bacterial cell volume with the Coulter counter</article-title><source>Journal of Bacteriology</source><volume>168</volume><fpage>1466</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1128/JB.168.3.1466-1467.1986</pub-id><pub-id pub-id-type="pmid">3536882</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landsberger</surname> <given-names>M</given-names></name><name><surname>Gandon</surname> <given-names>S</given-names></name><name><surname>Meaden</surname> <given-names>S</given-names></name><name><surname>Rollie</surname> <given-names>C</given-names></name><name><surname>Chevallereau</surname> <given-names>A</given-names></name><name><surname>Chabas</surname> <given-names>H</given-names></name><name><surname>Buckling</surname> <given-names>A</given-names></name><name><surname>Westra</surname> <given-names>ER</given-names></name><name><surname>van Houte</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Anti-CRISPR phages cooperate to overcome CRISPR-Cas immunity</article-title><source>Cell</source><volume>174</volume><fpage>908</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.05.058</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname> <given-names>RK</given-names></name><name><surname>Ye</surname> <given-names>Q</given-names></name><name><surname>Birkholz</surname> <given-names>EA</given-names></name><name><surname>Berg</surname> <given-names>KR</given-names></name><name><surname>Patel</surname> <given-names>L</given-names></name><name><surname>Mathews</surname> <given-names>IT</given-names></name><name><surname>Watrous</surname> <given-names>JD</given-names></name><name><surname>Ego</surname> <given-names>K</given-names></name><name><surname>Whiteley</surname> <given-names>AT</given-names></name><name><surname>Lowey</surname> <given-names>B</given-names></name><name><surname>Mekalanos</surname> <given-names>JJ</given-names></name><name><surname>Kranzusch</surname> <given-names>PJ</given-names></name><name><surname>Jain</surname> <given-names>M</given-names></name><name><surname>Pogliano</surname> <given-names>J</given-names></name><name><surname>Corbett</surname> <given-names>KD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure and mechanism of a cyclic Trinucleotide-Activated bacterial endonuclease mediating bacteriophage immunity</article-title><source>Molecular Cell</source><volume>77</volume><fpage>723</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.12.010</pub-id><pub-id pub-id-type="pmid">31932164</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Yin</surname> <given-names>Q</given-names></name><name><surname>Kuss</surname> <given-names>P</given-names></name><name><surname>Maliga</surname> <given-names>Z</given-names></name><name><surname>Millán</surname> <given-names>JL</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Mitchison</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hydrolysis of 2'3'-cGAMP by ENPP1 and design of nonhydrolyzable analogs</article-title><source>Nature Chemical Biology</source><volume>10</volume><fpage>1043</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1661</pub-id><pub-id pub-id-type="pmid">25344812</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Ye</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Liang</surname> <given-names>Y</given-names></name><name><surname>She</surname> <given-names>Q</given-names></name><name><surname>Peng</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transcriptional regulator-mediated activation of adaptation genes triggers CRISPR de novo spacer acquisition</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>1044</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1383</pub-id><pub-id pub-id-type="pmid">25567986</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Ye</surname> <given-names>Q</given-names></name><name><surname>Pan</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Peng</surname> <given-names>W</given-names></name><name><surname>Liang</surname> <given-names>Y</given-names></name><name><surname>She</surname> <given-names>Q</given-names></name><name><surname>Peng</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Coupling transcriptional activation of CRISPR-Cas system and DNA repair genes by Csa3a in Sulfolobus islandicus</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>8978</fpage><lpage>8992</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx612</pub-id><pub-id pub-id-type="pmid">28911114</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarova</surname> <given-names>KS</given-names></name><name><surname>Wolf</surname> <given-names>YI</given-names></name><name><surname>Iranzo</surname> <given-names>J</given-names></name><name><surname>Shmakov</surname> <given-names>SA</given-names></name><name><surname>Alkhnbashi</surname> <given-names>OS</given-names></name><name><surname>Brouns</surname> <given-names>SJJ</given-names></name><name><surname>Charpentier</surname> <given-names>E</given-names></name><name><surname>Cheng</surname> <given-names>D</given-names></name><name><surname>Haft</surname> <given-names>DH</given-names></name><name><surname>Horvath</surname> <given-names>P</given-names></name><name><surname>Moineau</surname> <given-names>S</given-names></name><name><surname>Mojica</surname> <given-names>FJM</given-names></name><name><surname>Scott</surname> <given-names>D</given-names></name><name><surname>Shah</surname> <given-names>SA</given-names></name><name><surname>Siksnys</surname> <given-names>V</given-names></name><name><surname>Terns</surname> <given-names>MP</given-names></name><name><surname>Venclovas</surname> <given-names>Č</given-names></name><name><surname>White</surname> <given-names>MF</given-names></name><name><surname>Yakunin</surname> <given-names>AF</given-names></name><name><surname>Yan</surname> <given-names>W</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Garrett</surname> <given-names>RA</given-names></name><name><surname>Backofen</surname> <given-names>R</given-names></name><name><surname>van der Oost</surname> <given-names>J</given-names></name><name><surname>Barrangou</surname> <given-names>R</given-names></name><name><surname>Koonin</surname> <given-names>EV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants</article-title><source>Nature Reviews Microbiology</source><volume>18</volume><fpage>67</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0299-x</pub-id><pub-id pub-id-type="pmid">31857715</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname> <given-names>SA</given-names></name><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Graham</surname> <given-names>S</given-names></name><name><surname>Rambo</surname> <given-names>R</given-names></name><name><surname>White</surname> <given-names>MF</given-names></name><name><surname>Gloster</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure and mechanism of a type III CRISPR defence DNA nuclease activated by cyclic oligoadenylate</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>500</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-14222-x</pub-id><pub-id pub-id-type="pmid">31980625</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meeske</surname> <given-names>AJ</given-names></name><name><surname>Nakandakari-Higa</surname> <given-names>S</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage</article-title><source>Nature</source><volume>570</volume><fpage>241</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1257-5</pub-id><pub-id pub-id-type="pmid">31142834</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasef</surname> <given-names>M</given-names></name><name><surname>Muffly</surname> <given-names>MC</given-names></name><name><surname>Beckman</surname> <given-names>AB</given-names></name><name><surname>Rowe</surname> <given-names>SJ</given-names></name><name><surname>Walker</surname> <given-names>FC</given-names></name><name><surname>Hatoum-Aslan</surname> <given-names>A</given-names></name><name><surname>Dunkle</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Regulation of cyclic oligoadenylate synthesis by the <italic>Staphylococcus epidermidis</italic> Cas10-Csm complex</article-title><source>RNA</source><volume>25</volume><fpage>948</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1261/rna.070417.119</pub-id><pub-id pub-id-type="pmid">31076459</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niewoehner</surname> <given-names>O</given-names></name><name><surname>Garcia-Doval</surname> <given-names>C</given-names></name><name><surname>Rostøl</surname> <given-names>JT</given-names></name><name><surname>Berk</surname> <given-names>C</given-names></name><name><surname>Schwede</surname> <given-names>F</given-names></name><name><surname>Bigler</surname> <given-names>L</given-names></name><name><surname>Hall</surname> <given-names>J</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name><name><surname>Jinek</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers</article-title><source>Nature</source><volume>548</volume><fpage>543</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/nature23467</pub-id><pub-id pub-id-type="pmid">28722012</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortmann</surname> <given-names>AC</given-names></name><name><surname>Brumfield</surname> <given-names>SK</given-names></name><name><surname>Walther</surname> <given-names>J</given-names></name><name><surname>McInnerney</surname> <given-names>K</given-names></name><name><surname>Brouns</surname> <given-names>SJ</given-names></name><name><surname>van de Werken</surname> <given-names>HJ</given-names></name><name><surname>Bothner</surname> <given-names>B</given-names></name><name><surname>Douglas</surname> <given-names>T</given-names></name><name><surname>van de Oost</surname> <given-names>J</given-names></name><name><surname>Young</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transcriptome analysis of infection of the archaeon <italic>Sulfolobus solfataricus</italic> with Sulfolobus turreted icosahedral virus</article-title><source>Journal of Virology</source><volume>82</volume><fpage>4874</fpage><lpage>4883</lpage><pub-id pub-id-type="doi">10.1128/JVI.02583-07</pub-id><pub-id pub-id-type="pmid">18337566</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rostøl</surname> <given-names>JT</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Non-specific degradation of transcripts promotes plasmid clearance during type III-A CRISPR-Cas immunity</article-title><source>Nature Microbiology</source><volume>4</volume><fpage>656</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0353-x</pub-id><pub-id pub-id-type="pmid">30692669</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouillon</surname> <given-names>C</given-names></name><name><surname>Athukoralage</surname> <given-names>JS</given-names></name><name><surname>Graham</surname> <given-names>S</given-names></name><name><surname>Grüschow</surname> <given-names>S</given-names></name><name><surname>White</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Control of cyclic oligoadenylate synthesis in a type III CRISPR system</article-title><source>eLife</source><volume>7</volume><elocation-id>e36734</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.36734</pub-id><pub-id pub-id-type="pmid">29963983</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouillon</surname> <given-names>C</given-names></name><name><surname>Athukoralage</surname> <given-names>JS</given-names></name><name><surname>Graham</surname> <given-names>S</given-names></name><name><surname>Grüschow</surname> <given-names>S</given-names></name><name><surname>White</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Investigation of the cyclic oligoadenylate signaling pathway of type III CRISPR systems</article-title><source>Methods in Enzymology</source><volume>616</volume><fpage>191</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2018.10.020</pub-id><pub-id pub-id-type="pmid">30691643</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samai</surname> <given-names>P</given-names></name><name><surname>Pyenson</surname> <given-names>N</given-names></name><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Goldberg</surname> <given-names>GW</given-names></name><name><surname>Hatoum-Aslan</surname> <given-names>A</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Co-transcriptional DNA and RNA cleavage during type III CRISPR-Cas immunity</article-title><source>Cell</source><volume>161</volume><fpage>1164</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.04.027</pub-id><pub-id pub-id-type="pmid">25959775</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorek</surname> <given-names>R</given-names></name><name><surname>Lawrence</surname> <given-names>CM</given-names></name><name><surname>Wiedenheft</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CRISPR-mediated adaptive immune systems in Bacteria and archaea</article-title><source>Annual Review of Biochemistry</source><volume>82</volume><fpage>237</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-072911-172315</pub-id><pub-id pub-id-type="pmid">23495939</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamulaitis</surname> <given-names>G</given-names></name><name><surname>Kazlauskiene</surname> <given-names>M</given-names></name><name><surname>Manakova</surname> <given-names>E</given-names></name><name><surname>Venclovas</surname> <given-names>Č</given-names></name><name><surname>Nwokeoji</surname> <given-names>AO</given-names></name><name><surname>Dickman</surname> <given-names>MJ</given-names></name><name><surname>Horvath</surname> <given-names>P</given-names></name><name><surname>Siksnys</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus</article-title><source>Molecular Cell</source><volume>56</volume><fpage>506</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.09.027</pub-id><pub-id pub-id-type="pmid">25458845</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamulaitis</surname> <given-names>G</given-names></name><name><surname>Venclovas</surname> <given-names>Č</given-names></name><name><surname>Siksnys</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Type III CRISPR-Cas immunity: major differences brushed aside</article-title><source>Trends in Microbiology</source><volume>25</volume><fpage>49</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.09.012</pub-id><pub-id pub-id-type="pmid">27773522</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname> <given-names>BNJ</given-names></name><name><surname>Vercoe</surname> <given-names>RB</given-names></name><name><surname>Salmond</surname> <given-names>GPC</given-names></name><name><surname>Westra</surname> <given-names>ER</given-names></name><name><surname>Staals</surname> <given-names>RHJ</given-names></name><name><surname>Fineran</surname> <given-names>PC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Type I-F CRISPR-Cas resistance against virulent phages results in abortive infection and provides population-level immunity</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5526</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13445-2</pub-id><pub-id pub-id-type="pmid">31797922</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteley</surname> <given-names>AT</given-names></name><name><surname>Eaglesham</surname> <given-names>JB</given-names></name><name><surname>de Oliveira Mann</surname> <given-names>CC</given-names></name><name><surname>Morehouse</surname> <given-names>BR</given-names></name><name><surname>Lowey</surname> <given-names>B</given-names></name><name><surname>Nieminen</surname> <given-names>EA</given-names></name><name><surname>Danilchanka</surname> <given-names>O</given-names></name><name><surname>King</surname> <given-names>DS</given-names></name><name><surname>Lee</surname> <given-names>ASY</given-names></name><name><surname>Mekalanos</surname> <given-names>JJ</given-names></name><name><surname>Kranzusch</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bacterial cGAS-like enzymes synthesize diverse nucleotide signals</article-title><source>Nature</source><volume>567</volume><fpage>194</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0953-5</pub-id><pub-id pub-id-type="pmid">30787435</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wurtzel</surname> <given-names>O</given-names></name><name><surname>Sapra</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>F</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Simmons</surname> <given-names>BA</given-names></name><name><surname>Sorek</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A single-base resolution map of an archaeal transcriptome</article-title><source>Genome Research</source><volume>20</volume><fpage>133</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1101/gr.100396.109</pub-id><pub-id pub-id-type="pmid">19884261</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Klompe</surname> <given-names>SE</given-names></name><name><surname>Vlot</surname> <given-names>M</given-names></name><name><surname>van der Oost</surname> <given-names>J</given-names></name><name><surname>Staals</surname> <given-names>RHJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Shooting the messenger: rna-targetting CRISPR-Cas systems</article-title><source>Bioscience Reports</source><volume>38</volume><elocation-id>BSR20170788</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20170788</pub-id><pub-id pub-id-type="pmid">29748239</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55852.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Wiedenheft</surname><given-names>Blake</given-names></name><role>Reviewing Editor</role><aff><institution>Montana State University</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Lawrence</surname><given-names>Martin</given-names> </name><role>Reviewer</role><aff><institution/></aff></contrib><contrib contrib-type="reviewer"><name><surname>Sorek</surname><given-names>Rotem</given-names> </name><role>Reviewer</role><aff><institution>Weizmann Institute of Science</institution></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>Thank you for submitting your article &quot;The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Gisela Storz as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Philip Kranzusch (Reviewer #1); Martin Lawrence (Reviewer #2); Rotem Sorek (Reviewer #3).</p><p>The reviewers universally agree that this work is nearly ready for publication. No additional experiments are requested.</p><p>Summary:</p><p>It is becoming increasingly clear that cyclic nucleotides play a critical role in the host response to a viral infection and that viruses have evolved mechanisms to intercept these signaling molecules. In this work, the authors focused on the synthesis of cyclic-oligo-adenylate (cA<sub>4</sub>) produced by the type-III CRISPR system in <italic>Sulfolobus solfataricus</italic>, the immune proteins that are activated by cA<sub>4</sub>, and viral anti-CRISPR proteins that degrade cA<sub>4</sub>. Biochemical data is used to build a kinetic model, which helps explains how cyclases and ring nucleases govern cyclic nucleotide levels and determine infection outcomes in virus-host conflict.</p><p>Essential revisions:</p><p>1) Rates of cA<sub>4</sub> synthesis by the <italic>S. solfataricus</italic> Csm complex have been previously measured (Rouillon et al., 2018; Rouillon et al., 2019). These rates should be incorporated into the mathematical model to understand how the relative rates of cA<sub>4</sub> synthesis and cA<sub>4</sub> degradation may influence effector function dynamics.</p><p>2) The current model does not take into account previously observations from the lab demonstrating that cA<sub>4</sub> synthesis wanes after ~10 min if no new activating RNA is delivered to the system. Please discuss this in the context of your model.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55852.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Rates of cA<sub>4</sub> synthesis by the <italic>S. solfataricus</italic> Csm complex have been previously measured (Rouillon et al., 2018; Rouillon et al., 2019). These rates should be incorporated into the mathematical model to understand how the relative rates of cA<sub>4</sub> synthesis and cA<sub>4</sub> degradation may influence effector function dynamics.</p></disp-quote><p>We agree that this would strengthen the model. We have determined the rate of cA<sub>4</sub> synthesis (Figure 2—figure supplement 2) from previously published data (Rouillon et al., 2018) and have incorporated this into the model. We have also adjusted the kinetic parameters of our model to the reaction temperature of 70 °C, which better represents infection kinetics at the growth temperature of <italic>S. solfataricus</italic>. We have also increased the cellular RNA concentration to 1000 µM, from 100 µM in the previous model, which we believe better represents cellular conditions and means that RNA is never fully depleted in the simulations. For comparison and transparency, we include a supplementary version of Figure 6 with simulations starting at fixed cA<sub>4</sub> concentrations (as in the original submission) carried with the current model as per our initial submission. See Author response images 1 and 2. Ultimately, the changes we have made, including incorporation of the rate of cA<sub>4</sub> synthesis do not radically alter any of our previous conclusions.</p><fig id="respfig1"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-resp-fig1-v2.tif"/></fig><fig id="respfig2"><label>Author response image 2.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55852-resp-fig2-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2) The current model does not take into account previously observations from the lab demonstrating that cA<sub>4</sub> synthesis wanes after ~10 min if no new activating RNA is delivered to the system. Please discuss this in the context of your model.</p></disp-quote><p>This query relates to point 1, and we have addressed this point in the new model, which now incorporates the time dependent synthesis of cA<sub>4</sub>, dependent on the concentration of target RNA.</p></body></sub-article></article>